Sickle Cell Disease Clinical Trial
Official title:
BEATS 2: The Effects of Music Therapy on Young Adults With Sickle Cell Disease
Verified date | October 2018 |
Source | University Hospitals Cleveland Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to investigate the effects of the BEATS music therapy program on
the self-efficacy, trust, knowledge, and adherence of young adult patients with SCD.
Primary Hypotheses:
Compared to baseline, young adult patients with SCD who receive the music therapy
interventions will report:
Higher sickle cell self-efficacy as measured by the Sickle Cell Self Efficacy Scale (SCSES),
Higher trust in health care providers as measured by the Wake Forest Trust in the Medical
Profession Scale, and Higher SCD knowledge as measured by the Seidman Sickle Cell Knowledge
Quiz.
Secondary Hypotheses Compared to the one year prior to the study period, young adults with
SCD who receive the music therapy interventions will have a higher rate of adherence to
clinic appointments during the one-year study period.
Additional Questions Do music therapy interventions influence the rate of hospital
utilization as measured by ED visits, Acute Care Clinic (ACC) visits, and admissions during
the study period compared to the previous year? Do music therapy interventions influence
adherence to hydroxyurea therapy for patients receiving hydroxyurea as measured by change in
mean corpuscular volume (MCV) during the study period? Do music therapy interventions
influence adherence to iron chelation therapy for patients receiving iron chelation therapy
as measured by ferritin count during the study period? Does the schedule of music therapy
interventions in this study improve outcomes more significantly than the schedule of music
therapy interventions from [IRB# 03-15-30]?
Status | Completed |
Enrollment | 50 |
Est. completion date | September 30, 2018 |
Est. primary completion date | September 30, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 35 Years |
Eligibility |
Inclusion Criteria: - Subject is between 18 and 35 years of age - Subject is diagnosed with sickle cell disease - Subject is able to speak and understand English - Subject has a working email address. - Subject has access to a mobile device with email capabilities. Exclusion Criteria: - Subject has significant hearing impairment that has not been corrected - Subject has significant visual impairment that has not been corrected |
Country | Name | City | State |
---|---|---|---|
United States | University Hospitals Seidman Cancer Center | Cleveland | Ohio |
Lead Sponsor | Collaborator |
---|---|
University Hospitals Cleveland Medical Center | Kulas Foundation |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from baseline in scores on the Sickle Cell Self-Efficacy Scale (SCSES) | Self-efficacy is the conviction that one can successfully execute the behavior required to produce the outcome. (Bandura, 1997, p. 193). The SCSES is a nine-item Likert scale originally developed for adults with sickle cell disease (Edwards, Telfair, Cecil, & Lenoci, 2000) and revised in a follow up study by Clay and Telfair (2007) for adolescents using a sample of 131 individuals age 11-19. |
Baseline, immediately after session 4, 4 weeks after session 4, immediately after session 8, 4 weeks after session 8. | |
Primary | Change from baseline in scores on the Wake Forest Trust in the Medical Profession Scale | Patient trust is the optimistic acceptance of a vulnerable situation in which the patient believes the health-care provider will take care of the patient's interests (Dugan, Trachtenberg, & Hall, 2005).The Wake Forest Trust in the Medical Profession Scale is a five-item scale in which respondents express their level of agreement with the following statements: 1) Sometimes doctors care more about what is convenient for them than about their patients' medical needs (reverse coded); 2) Doctors are extremely thorough and careful; 3) You completely trust doctors' decisions about which medical treatments are best; 4) A doctor would never mislead you about anything; 5) All in all, you trust your doctor completely. Responses are summed and scores are on a 5-25 scale, with higher values indicating greater trust. | Baseline, immediately after session 4, 4 weeks after session 4, immediately after session 8, 4 weeks after session 8. | |
Primary | Change from baseline in scores on the Seidman Sickle Cell Knowledge Quiz | Sickle Cell Disease knowledge will be measured using the Seidman Sickle Cell Knowledge Quiz developed specifically for this study. The Seidman Sickle Cell Knowledge Quiz is adapted from questions from the Sickle Cell Disease Knowledge Test (Kaslow et al., 2000) and How Much Do I Know About Sickle Cell Disease (Baskin, Collins, Kaslow, & Hsu, 2002). | Baseline, immediately after session 4, 4 weeks after session 4, immediately after session 8, 4 weeks after session 8. | |
Secondary | Change from baseline in rate of adherence to clinic appointments during the one-year study period. | Adherence is the extent to which a person's behavior coincides with medical or prescribed health advice (Julius, 2009).Adherence will be measured regularly throughout the study via medical record review. In order to assess adherence, the following data will be obtained from the medical record on each patient throughout the study period: 1) Total scheduled clinic visits with Adult Sickle Cell Disease Clinic, 2) Number of missed clinic visits to Adult Sickle Cell Disease Clinic due to no show, cancellation, or rescheduling | Baseline, 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02227472 -
Working Memory and School Readiness in Preschool-Aged Children With Sickle Cell Disease
|
||
Recruiting |
NCT06301893 -
Uganda Sickle Surveillance Study (US-3)
|
||
Recruiting |
NCT04398628 -
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
|
||
Completed |
NCT02522104 -
Evaluation of the Impact of Renal Function on the Pharmacokinetics of SIKLOS ® (DARH)
|
Phase 4 | |
Recruiting |
NCT04688411 -
An mHealth Strategy to Improve Medication Adherence in Adolescents With Sickle Cell Disease
|
N/A | |
Terminated |
NCT03615924 -
Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease
|
Phase 3 | |
Not yet recruiting |
NCT06300723 -
Clinical Study of BRL-101 in Severe SCD
|
N/A | |
Recruiting |
NCT03937817 -
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
|
||
Completed |
NCT04917783 -
Health Literacy - Neurocognitive Screening in Pediatric SCD
|
N/A | |
Completed |
NCT04134299 -
To Assess Safety, Tolerability and Physiological Effects on Structure and Function of AXA4010 in Subjects With Sickle Cell Disease
|
N/A | |
Completed |
NCT02580565 -
Prevalence of Problematic Use of Equimolar Mixture of Oxygen and Nitrous Oxide and Analgesics in the Sickle-cell Disease
|
||
Recruiting |
NCT04754711 -
Interest of Nutritional Care of Children With Sickle Cell Disease on Bone Mineral Density and Body Composition
|
N/A | |
Completed |
NCT04388241 -
Preliminary Feasibility and Efficacy of Behavioral Intervention to Reduce Pain-Related Disability in Pediatric SCD
|
N/A | |
Recruiting |
NCT05431088 -
A Phase 2/3 Study in Adult and Pediatric Participants With SCD
|
Phase 2/Phase 3 | |
Completed |
NCT01158794 -
Genes Influencing Iron Overload State
|
||
Recruiting |
NCT03027258 -
Point-of-Delivery Prenatal Test Results Through mHealth to Improve Birth Outcome
|
N/A | |
Withdrawn |
NCT02960503 -
Macrolide Therapy to Improve Forced Expiratory Volume in 1 Second in Adults With Sickle Cell Disease
|
Phase 1/Phase 2 | |
Completed |
NCT02567695 -
A Single-Dose Relative Bioavailability Study Of GBT440 300 mg Capsules in Healthy Subjects
|
Phase 1 | |
Not yet recruiting |
NCT02525107 -
Prevention of Vaso-occlusive Painful Crisis by Using Omega-3 Fatty Acid Supplements
|
Phase 3 | |
Withdrawn |
NCT02630394 -
A Pilot Study of Azithromycin Prophylaxis for Acute Chest Syndrome in Sickle Cell Disease
|
Phase 1 |